• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Am Coll Cardiol. Management of Acute Myocardial Infarction During the COVID-19 Pandemic

tetano

Editor, Senior Moderator
J Am Coll Cardiol. 2020 Apr 18. pii: S0735-1097(20)35026-9. doi: 10.1016/j.jacc.2020.04.039. [Epub ahead of print]
Management of Acute Myocardial Infarction During the COVID-19 Pandemic.


Mahmud E[SUP]1[/SUP], Dauerman HL[SUP]2[/SUP], Welt FG[SUP]3[/SUP], Messenger JC[SUP]4[/SUP], Rao SV[SUP]5[/SUP], Grines C[SUP]6[/SUP], Mattu A[SUP]7[/SUP], Kirtane AJ[SUP]8[/SUP], Jauhar R[SUP]9[/SUP], Meraj P[SUP]10[/SUP], Rokos IC[SUP]11[/SUP], Rumsfeld JS[SUP]12[/SUP], Henry TD[SUP]13[/SUP].

Author information




Abstract

The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option.
Copyright ? 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.



KEYWORDS:

COVID-19; STEMI; acute myocardial infarction; emergency medical system; fibrinolysis; percutaneous coronary intervention


PMID:32330544DOI:10.1016/j.jacc.2020.04.039
 
Back
Top Bottom